California Public Employees Retirement System Purchases 121,813 Shares of Bristol Myers Squibb Company $BMY

California Public Employees Retirement System grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.4% in the first quarter, HoldingsChannel reports. The fund owned 5,233,948 shares of the biopharmaceutical company’s stock after acquiring an additional 121,813 shares during the period. California Public Employees Retirement System’s holdings in Bristol Myers Squibb were worth $317,439,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Quadrant Private Wealth Management LLC grew its position in Bristol Myers Squibb by 2.2% in the first quarter. Quadrant Private Wealth Management LLC now owns 12,163 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 261 shares in the last quarter. Kera Capital Partners Inc. lifted its position in Bristol Myers Squibb by 20.8% during the 1st quarter. Kera Capital Partners Inc. now owns 11,538 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 1,984 shares in the last quarter. Cornerstone Planning Group LLC boosted its stake in shares of Bristol Myers Squibb by 29.8% during the 1st quarter. Cornerstone Planning Group LLC now owns 801 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 184 shares during the last quarter. Angeles Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 0.9% during the 1st quarter. Angeles Wealth Management LLC now owns 20,951 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 196 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of Bristol Myers Squibb by 19.6% in the 1st quarter. Bessemer Group Inc. now owns 70,632 shares of the biopharmaceutical company’s stock valued at $4,283,000 after acquiring an additional 11,584 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 0.3%

Shares of BMY opened at $60.71 on Friday. The firm has a market cap of $123.97 billion, a P/E ratio of 17.05, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The firm’s 50-day simple moving average is $57.02 and its 200 day simple moving average is $57.78.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period last year, the business posted $1.80 earnings per share. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is 70.79%.

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. Bank of America dropped their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $61.25.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY.
• Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself.
• Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.